drugset
drugset / Trial / NCT01477489

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

NCT01477489 ↗

Phase 1 Completed 33 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.

Timeline

Start
2012-01
Primary completion
2014-10
Completion
2017-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Veliparib Small molecule 50 mg Oral
Subject Veliparib Small molecule 100 mg Oral
Subject Veliparib Small molecule 150 mg Oral
Subject Veliparib Small molecule 200 mg Oral

Indications

breast cancer